Healthcare 1 April 2026 - 22 May 2026

Serve Robotics Stock Drops Before Long Weekend, Hospital Project Still Needs Funding
····

Serve Robotics Stock Drops Before Long Weekend, Hospital Project Still Needs Funding

Serve Robotics Inc. shares fell Friday even as the broader U.S. market rose. Investors looked at the company’s new hospital automation move but had concerns about funding and execution risks ahead of the Memorial Day holiday. SERV ended regular trading on Nasdaq at $8.70, off 1.25%. Shares traded between $8.62 and $9.01 during the session. In after-hours trade, SERV was last quoted at $8.73. Volume at the close was 3.84 million shares. Market cap stood near $673 million, according to Google Finance.
May 22, 2026
Atrium Therapeutics Stock Climbs: The Key FDA Filing Investors Are Watching Now
····

Atrium Therapeutics Stock Climbs: The Key FDA Filing Investors Are Watching Now

Atrium Therapeutics shares rose 1.9% to $12.96 in Thursday afternoon trading, giving the San Diego-based ribonucleic acid drug developer a market value of about $222 million. The Nasdaq-listed stock traded between $12.62 and $13.07, with volume at 152,813 shares in the latest available market data. The move matters now because Atrium is still being priced more on cash, platform promise and upcoming regulatory steps than on clinical results. Its first big near-term marker is an Investigational New Drug application, or IND — a request to regulators to begin human testing — for ATR 1072, which the company expects to submit in the second half of 2026.
May 21, 2026
RADX Shares Slip Ahead of Cancer-Imaging Update
····

RADX Shares Slip Ahead of Cancer-Imaging Update

Radiopharm Theranostics’ U.S. shares slipped a bit in light Nasdaq trading on Thursday. Investors are waiting for more updates on the Australian biotech’s top cancer-imaging project. The American depositary shares closed at $4.52, off 6 cents. The last trade was at 9:33 a.m. EDT and showed just 325 shares. That’s thin volume compared with the 161,513-share average daily volume Zacks cited earlier this month.
May 21, 2026
CG Oncology Shares Gain Ahead of Bladder Cancer Update; Wolfe Urges Caution
···

CG Oncology Shares Gain Ahead of Bladder Cancer Update; Wolfe Urges Caution

CG Oncology shares edged higher Wednesday as traders looked for direction and watched for the next update on its bladder-cancer drug, cretostimogene grenadenorepvec. The stock was recently quoted at $64.76, up 2.3%. Volume was near 768,000 shares. CG Oncology isn’t just a small biotech with a long runway anymore. The stock now trades around a near-term trial readout, a planned regulatory filing, and early Wall Street arguments over how quickly the drug could move if it wins approval. The company said it plans a biologics license application, or BLA, which is the main U.S. route for getting a biologic medicine cleared.
May 20, 2026
GSK Shares Gain After Arexvy Approval for More Adults in Japan
····

GSK Shares Gain After Arexvy Approval for More Adults in Japan

GSK shares traded higher in London on Monday after Japan granted expanded approval for Arexvy, the company’s RSV vaccine. Investors got a new regulatory boost for vaccines as GSK also kept buying back its own shares. Shares traded at 1,879.81 pence, gaining 0.93%, after starting at 1,855.50p and reaching as high as 1,880.42p, market data show. The FTSE 100 was up 0.99% at 10,296.36.
May 18, 2026
Advanced Medical Solutions dives as TA Associates deal collapses
····

Advanced Medical Solutions dives as TA Associates deal collapses

Advanced Medical Solutions Group shares fell hard Monday after TA Associates confirmed it will not move ahead with a takeover of the British medical supplier. The AIM-listed stock had traded under bid speculation since April. That is in focus now because the market had already priced in odds of a deal. A takeover premium had appeared after Advanced Medical Solutions said last month it was talking with TA about a possible full buyout. Investors had added extra value to the shares on hopes a buyer would pay above market price.
May 18, 2026
Cochlear Shares Drop Again As Investors Question the Profit Shock
····

Cochlear Shares Drop Again As Investors Question the Profit Shock

Cochlear Ltd dropped 4.64% to A$95.42 on Thursday, stretching its decline to a third straight session and leaving the Australian hearing-implant maker close to lows reached during last month’s record slide. Volume spiked, too—roughly 671,000 shares changed hands, up from 351,000 the previous day. This shift lands hard for investors still wrestling with how to value a name that used to be pegged as a reliable health-care growth play. Back on April 22, Reuters said Cochlear shares cratered 40.7%—the worst single-day performance the stock’s ever posted—after the company slashed its full-year profit outlook and pointed to sluggish demand in developed markets, Middle East unrest, and currency headwinds.
May 15, 2026
Spire Healthcare Group PLC Shares Surge as Toscafund’s £1bn Takeover Bid Revives Sale Talks
····

Spire Healthcare Group PLC Shares Surge as Toscafund’s £1bn Takeover Bid Revives Sale Talks

Shares of Spire Healthcare Group PLC surged Thursday, following news that Toscafund Asset Management—its number two shareholder—has put forward a non-binding cash bid valuing the hospital group at roughly £1.01 billion, or 250 pence per share. Timing is key here. Spire’s strategic review has been underway for a while, but now the sale process is back in play—earlier takeover talks with Bridgepoint and Triton fizzled out, stalling momentum. Reuters said Triton walked away in March.
May 14, 2026
GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight
······

GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight

A U.S. federal judge has tossed Acuitas Therapeutics Inc.’s attempt to shield Pfizer and BioNTech’s Comirnaty Covid-19 vaccine from GSK’s patent claims, handing the British pharma giant a procedural victory in the ongoing mRNA legal fight. Judge Gregory B. Williams sided with GSK, dismissing the Acuitas case on grounds that the court lacked subject-matter jurisdiction—essentially, it didn’t have the authority to weigh in as presented, according to Bloomberg Law on Friday. The decision keeps the spotlight fixed on the main Delaware showdown involving GSK, Pfizer and BioNTech, instead of letting a supplier-driven lawsuit muddy the waters. Back in 2024, GSK filed suit against Pfizer and BioNTech, claiming Comirnaty stepped on patents for mRNA vaccine technology the company says it created
May 9, 2026
Star Health’s Cheaper Insurance Bet Meets Claims Scrutiny as Payouts Jump
···

Star Health’s Cheaper Insurance Bet Meets Claims Scrutiny as Payouts Jump

Star Health and Allied Insurance is set to roll out two budget health insurance offerings aimed at smaller Indian cities within this fiscal year, targeting price-conscious consumers as higher payouts and a recent consumer-forum directive put its claims process under the microscope. Timing, here, is crucial. Health insurance policyholders are contending with steeper hospital charges, and according to Star Health Managing Director and CEO Anand Roy in comments to the Economic Times, “annual hikes on health insurance premiums are here to stay.” The sector is being squeezed by medical inflation running at 13% to 14% annually. Medical inflation captures rising costs tied to treatment, hospitals, and healthcare services.
May 7, 2026
BioNTech Stock Faces A Hard Cancer Pivot Test After Q1 Loss Widens And 1,860 Jobs Are Hit
···

BioNTech Stock Faces A Hard Cancer Pivot Test After Q1 Loss Widens And 1,860 Jobs Are Hit

MAINZ, Germany, May 5, 2026, 13:13 CEST BioNTech announced plans Tuesday to leave several manufacturing sites, moves that could impact as many as 1,860 jobs. The biotech is also launching a buyback of up to $1 billion in its U.S.-listed shares, stepping up its reset after the pandemic as its quarterly loss grew. The Mainz-based company is sticking to its 2026 revenue target, leaning more on its cancer drug pipeline as it looks ahead.
May 5, 2026
Medibank Private Ltd ASX:MPL Shares Face Monday Test After 5.10% Premium Rise
···

Medibank Private Ltd ASX:MPL Shares Face Monday Test After 5.10% Premium Rise

Medibank Private Ltd heads into Monday with shares last changing hands at A$4.720, a gain of 2.9 cents, as the Australian market stood in its pre-open order-entry window. The most recent filing for the company, according to ASX data, was a “change in substantial holding” posted on April 29. Regular ASX trading is slated to kick off at roughly 9:59:45 Sydney time. The reason for the timing is straightforward: April’s premium reset has shifted from green light to hitting wallets. The government signed off on a 4.41% average hike for private health insurance starting April 1. Medibank, for its part, raised its Medibank and ahm premiums by an average 5.10%.
May 3, 2026
4DMedical Stock Faces Its Next Big Test After GSK Deal, ASX 200 Entry
···

4DMedical Stock Faces Its Next Big Test After GSK Deal, ASX 200 Entry

4DMedical Ltd heads into Monday trading with investors assessing whether a surge in hospital scan volumes and a new GSK research contract can justify a stock that has swung from A$0.23 to A$7.55 over the past year. Shares last traded at A$4.02, up 0.25% in the previous ASX session, giving the lung-imaging software company a market value of about A$2.37 billion. That matters now because the Melbourne-based company has moved into the S&P/ASX 200, raised A$233 million through two institutional placements this year, and reported a pro-forma cash balance of A$282.7 million at March 31. The cash gives 4DMedical room to push CT:VQ, its lung-imaging software, but the larger index profile also puts more pressure on management to turn reference-site
May 3, 2026
GSK Shares Bounce After Shingrix Surge, But Investors Spot One Big Catch
···

GSK Shares Bounce After Shingrix Surge, But Investors Spot One Big Catch

GSK ticked up in London on Thursday, with shares trading at 1,938 pence at 2:51 p.m. BST, up 1.04%. That comes after Wednesday’s 5.42% tumble, as investors digested a first-quarter profit beat that left questions unanswered about the sustainability of those gains. This quarter lands early in CEO Luke Miels’ tenure, a first look at whether GSK can chase that £40 billion sales target for 2031—even with the looming 2028 patent cliff for dolutegravir, its main HIV drug. Some investors, according to Reuters, asked if the earnings beat owed more to one-off items than underlying strength.
April 30, 2026
Reckitt Benckiser Durex Headache Deepens as China Price Scare Follows Weak Quarter
····

Reckitt Benckiser Durex Headache Deepens as China Price Scare Follows Weak Quarter

Reckitt Benckiser Group plc is under new pressure in China, with news of rising condom prices spreading quickly online. The viral warning has sparked chatter about stockpiling, hitting one of the company’s vital growth markets only days after it posted quarterly sales that fell short of forecasts. This issue is moving front and center after China and India gave Reckitt’s emerging markets results a lift in the first quarter. Durex sales in China, though, have stalled—condoms and contraceptive pills are now hit with a 13% value-added tax, pushing up prices throughout the supply chain. Karex Bhd, which makes more condoms than anyone and counts Durex and Trojan among its customers, says it may hike prices 20% to 30% if supply
April 25, 2026
ConvaTec Shares Drop Again as Wound-Care Warning Puts 2026 Growth Plan in Focus
····

ConvaTec Shares Drop Again as Wound-Care Warning Puts 2026 Growth Plan in Focus

Convatec Group Plc dropped in London trading on Friday, putting the FTSE 100 medical-products company back in the spotlight. Investors are now sizing up its 2026 growth ambitions, with new signals of weakness emerging in certain segments of the wound-care market. Convatec shares finished the day at £2.21, down 1.69%—a steeper drop than the broader market. The closing price, according to MarketWatch, leaves the stock trading 29.05% beneath its 52-week high of £3.11.
April 24, 2026
CSL Limited Stock Hits 2017 Low After Pentagon Flu Vaccine Shift Shakes Seqirus Outlook
···

CSL Limited Stock Hits 2017 Low After Pentagon Flu Vaccine Shift Shakes Seqirus Outlook

CSL Limited shares slid to lows not seen since 2017, hit by news that the U.S. military has scrapped its long-standing mandate for troops to get yearly flu shots. The move throws another demand hurdle at the Australian biotech’s vaccine arm. Pressure is already on CSL. The Seqirus business brings in revenue with flu vaccines, and the U.S. stands as its top market. After softer demand for flu shots, a sluggish plasma rebound, and a string of earnings misses, investors have shaved value off the shares. Reuters said CSL stock slid up to 0.8% Thursday, putting it more than 25% lower in 2026.
April 23, 2026
GSK Shares Slip as U.S.-UK Drug Deal Eases Tariff Threat Before April Results
···

GSK Shares Slip as U.S.-UK Drug Deal Eases Tariff Threat Before April Results

GSK's U.S. shares slipped roughly 0.7%, closing at $56.29 on Monday, as the market weighed the implications of a freshly completed U.S.-UK medicines agreement for the British pharma giant. This comes on the heels of recent moves around tariffs and drug pricing in the industry. Timing’s key here. GSK, one of the big pharma names protected by tariffs, lands its first-quarter report on April 29—so investors don’t have to wait long to see if that policy buffer is holding up.
April 6, 2026
GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
·······

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake

GSK plc wrapped up changes to ViiV Healthcare’s ownership structure on April 1. After Pfizer’s exit from the HIV-focused joint venture, Japan’s Shionogi bumped its stake up to 21.7%. GSK remains the majority owner with 78.3%, the company said. Timing is crucial here: ViiV is a core growth driver as GSK shifts focus toward specialty medicines. For 2025, GSK reported an 11% increase in HIV sales to 7.7 billion pounds, fueling a 17% jump in specialty medicines revenue.
April 2, 2026
GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake
···

GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake

GSK on Wednesday wrapped up changes to the structure of its HIV unit ViiV Healthcare. Japan’s Shionogi raised its stake to 21.7% as Pfizer exited the partnership entirely. GSK retains a majority holding at 78.3%. Timing is crucial here. HIV remains a cornerstone for GSK, and Chief Executive Luke Miels is gunning for annual sales topping 40 billion pounds by 2031. For 2025, GSK reported HIV sales up 11% to 7.7 billion pounds. Miels is eyeing 2026 as a launch-heavy stretch, promising quicker development cycles and sharper operational focus.
April 1, 2026
1 2 3 4 … 6